All antipsychotic side effects, present or past, can have a durable negative impact on patient's attitude toward antipsychotic treatment and adherence. Non-adherence is mainly determined, among other factors, by these negative attitudes, which are partly influenced by the experience of past or present antipsychotic-induced side effects.
The Emotional Stroop (ES) task (I. H. Gotlib & C. D. McCann, 1984) has been proposed as an experimental measure to assess the processing of emotion or the bias in attention of emotion-laden information. However, study results have not been consistent. To further examine its reliability for empirical research, the authors of this study administered the ES task to 33 participants on 2 separate occasions separated by 1 week. Results indicated that retest reliabilities for reaction times (RTs) derived from the 3 separate emotion conditions (manic, neutral, and depressive) across the 1 week interval were very high. However, consistent with previous research, the reliabilities were very low for the interference indices (manic and depressive). These low reliabilities reflect the very high intercorrelation between the RTs derived from the 3 conditions. The authors concluded that a better indicator of the reliability for this task is the individual RTs from each emotion condition.
Despite the limitations of a retrospective MR design, study results suggest equal therapeutic efficacy of OLZ and RIS in non-affective FEP and some therapeutic advantages of OLZ compared to RIS in affective FEP patients, especially in those with acute mania. Results may serve as hypotheses for future randomised controlled trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.